Dingwei Dai1, James A Feinstein, Wynne Morrison, Athena F Zuppa, Chris Feudtner. 1. 1Pediatric Advanced Care Team and the Center for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia; Philadelphia, PA. 2Adult and Child Consortium for Health Outcomes Research and Delivery Science, Children's Hospital Colorado, Aurora, CO. 3Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. 4Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia; Philadelphia, PA. 5Department of Pediatrics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. 6Center for Clinical Pharmacology, The Children's Hospital of Philadelphia; Philadelphia, PA.
Abstract
OBJECTIVES: Polypharmacy is common in hospitalized children in the United States and has been identified as a major risk factor for exposure to potential drug-drug interactions. Little is known about the characteristics and prevalence of exposure of pediatric patients to polypharmacy and potential drug-drug interactions in PICUs. DESIGN: Retrospective cohort study using the Pediatric Health Information System database. SETTING: Forty-two freestanding children's hospitals throughout the United States. PATIENTS: A total of 54,549 patients less than 18 years old cared for in PICUs in 2011. Patients in neonatal ICUs were not included. MEASUREMENTS AND MAIN RESULTS: PICU patients were on average exposed to 10 distinct drugs each hospital day and to 20 drugs cumulatively during their hospitalization. Seventy-five percent of patients were exposed to greater than or equal to one potential drug-drug interaction regardless of severity level, 6% to greater than or equal to one contraindicated potential drug-drug interaction, 69% to greater than or equal to one major potential drug-drug interaction, 57% to greater than or equal to one moderate potential drug-drug interaction, 19% to greater than or equal to one minor potential drug-drug interaction. Potential drug-drug interaction exposures were significantly associated with specific diagnoses (p < 0.001), presence of complex chronic conditions (p < 0.001), increasing number of total distinct drugs used (p < 0.001), increasing length of stay in PICU (p < 0.001), and white race (p < 0.001). CONCLUSIONS: Many PICU patients are exposed to substantial polypharmacy and potential drug-drug interactions. Future research should identify the risk of adverse drug events following specific potential drug-drug interaction exposures, especially the risk of adverse drug events due to multiple potential drug-drug interaction exposures, and determine the probability and magnitude of the actual harm (if any) for each specific potential drug-drug interaction, especially for multiple potential drug-drug interaction exposures.
OBJECTIVES: Polypharmacy is common in hospitalized children in the United States and has been identified as a major risk factor for exposure to potential drug-drug interactions. Little is known about the characteristics and prevalence of exposure of pediatric patients to polypharmacy and potential drug-drug interactions in PICUs. DESIGN: Retrospective cohort study using the Pediatric Health Information System database. SETTING: Forty-two freestanding children's hospitals throughout the United States. PATIENTS: A total of 54,549 patients less than 18 years old cared for in PICUs in 2011. Patients in neonatal ICUs were not included. MEASUREMENTS AND MAIN RESULTS: PICU patients were on average exposed to 10 distinct drugs each hospital day and to 20 drugs cumulatively during their hospitalization. Seventy-five percent of patients were exposed to greater than or equal to one potential drug-drug interaction regardless of severity level, 6% to greater than or equal to one contraindicated potential drug-drug interaction, 69% to greater than or equal to one major potential drug-drug interaction, 57% to greater than or equal to one moderate potential drug-drug interaction, 19% to greater than or equal to one minor potential drug-drug interaction. Potential drug-drug interaction exposures were significantly associated with specific diagnoses (p < 0.001), presence of complex chronic conditions (p < 0.001), increasing number of total distinct drugs used (p < 0.001), increasing length of stay in PICU (p < 0.001), and white race (p < 0.001). CONCLUSIONS: Many PICU patients are exposed to substantial polypharmacy and potential drug-drug interactions. Future research should identify the risk of adverse drug events following specific potential drug-drug interaction exposures, especially the risk of adverse drug events due to multiple potential drug-drug interaction exposures, and determine the probability and magnitude of the actual harm (if any) for each specific potential drug-drug interaction, especially for multiple potential drug-drug interaction exposures.
Authors: Juliana Barr; Gilles L Fraser; Kathleen Puntillo; E Wesley Ely; Céline Gélinas; Joseph F Dasta; Judy E Davidson; John W Devlin; John P Kress; Aaron M Joffe; Douglas B Coursin; Daniel L Herr; Avery Tung; Bryce R H Robinson; Dorrie K Fontaine; Michael A Ramsay; Richard R Riker; Curtis N Sessler; Brenda Pun; Yoanna Skrobik; Roman Jaeschke Journal: Crit Care Med Date: 2013-01 Impact factor: 7.598
Authors: Jeffrey D Edwards; Amy J Houtrow; Eduard E Vasilevskis; Roberta S Rehm; Barry P Markovitz; Robert J Graham; R Adams Dudley Journal: Crit Care Med Date: 2012-07 Impact factor: 7.598
Authors: James W Antoon; Matt Hall; Alison Herndon; Alison Carroll; My-Linh Ngo; Katherine L Freundlich; Justine C Stassun; Patricia Frost; David P Johnson; Swati B Chokshi; Charlotte M Brown; Whitney L Browning; James A Feinstein; Carlos G Grijalva; Derek J Williams Journal: Pediatrics Date: 2020-10-09 Impact factor: 7.124
Authors: Courtney Baker; James A Feinstein; Xuan Ma; Shari Bolen; Neal V Dawson; Negar Golchin; Alexis Horace; Lawrence C Kleinman; Sharon B Meropol; Elia M Pestana Knight; Almut G Winterstein; Paul M Bakaki Journal: Pharmacoepidemiol Drug Saf Date: 2019-02-06 Impact factor: 2.890
Authors: Susan E Maloney; Catherine E Creeley; Richard E Hartman; Carla M Yuede; Charles F Zorumski; Vesna Jevtovic-Todorovic; Krikor Dikranian; Kevin K Noguchi; Nuri B Farber; David F Wozniak Journal: Neurobiol Learn Mem Date: 2018-03-14 Impact factor: 2.877
Authors: Eman Biltaji; Elena Y Enioutina; Venkata Yellepeddi; Joseph E Rower; Catherine M T Sherwin; Robert M Ward; Richard S Lemons; Jonathan E Constance Journal: Leuk Lymphoma Date: 2020-04-07
Authors: Alexis E Horace; Negar Golchin; Elia M Pestana Knight; Neal V Dawson; Xuan Ma; James A Feinstein; Hannah K Johnson; Lawrence Kleinman; Paul M Bakaki Journal: Paediatr Drugs Date: 2020-02 Impact factor: 3.022
Authors: Negar Golchin; Hannah Johnson; Paul M Bakaki; Neal Dawson; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; James A Feinstein; Shari D Bolen; Lawrence C Kleinman; Alexis Horace Journal: Drugs Ther Perspect Date: 2019-07-12
Authors: Katherine A Hargreaves; Victoria M Pratt; Elizabeth B Medeiros; Ty C Lynnes; Caitlin A Granfield; Todd C Skaar; Aiko Iwata-Otsubo; Emma M Tillman Journal: Clin Transl Sci Date: 2021-01-25 Impact factor: 4.689